Article

Targeting PKLR and lipogenic enzymes through JNK inhibition to develop a therapeutic strategy for MASLD and MASH

2025-09-25

Abstract excerpt

<title>Abstract</title> <p>Pyruvate kinase liver and red blood cells (PKLR) has emerged as a key gene associated with metabolic dysfunction-associated steatotic liver disease (MASLD). Through a computational drug repurposing approach, we identified JNK-IN-5A as a small molecule that significantly inhibits the c-Jun N-terminal kinase (JNK) family and suppresses PKL expression in HepG2 cells. In this study, we furt...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 56a41033-2090-50f2-bd57-67aa6554e28a
DOI: 10.21203/rs.3.rs-7114368/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Targeting PKLR and lipogenic enzymes through JNK inhibition to develop a therapeutic strategy for MASLD and MASHDOI 10.21203/rs.3.rs-7114368/v1Read

PKLR-modulating compounds show promising effects for the treatment of hepatocellular carcinomaSemantic proximity Read

<i>Patolakaturohiniyadi Kashayam</i> , exerts anti-steatotic and anti-obesogenic effects via coordinated regulation of lipid metabolism, inflammation, and incretin signallingSemantic proximity Read

Integrative multi-omics and multi-trait analysis prioritizes regulatory mechanisms and genes for metabolic dysfunction-associated steatotic liver diseaseSemantic proximity Read

Explore of potential targets and mechanisms of hesperetin in treating metabolic dysfunction-associated steatosis liver disease via network pharmacology and in vitro experimentsSemantic proximity Read

Discovery of therapeutic agents targeting <i>PKLR</i> for NAFLD using drug repositioningSemantic proximity Read

Multi-tissue network analysis reveals the effect of JNK inhibition on dietary sucrose-induced metabolic dysfunction in ratsSemantic proximity Read

The pharmacodynamic and differential gene expression analysis of PPAR α/δ agonist GFT505 in CDAHFD-induced NASH modelSemantic proximity Read

Liver Kinome Profiling Identifies PS1145 as a Potential Therapeutic molecule for amelioration of Systemic Inflammation in Alcohol-related Liver DiseaseSemantic proximity Read

Metformin's Effect on Non-Alcoholic Fatty Liver Disease through the miR-200a-5p and AMPK/SERCA2b PathwaySemantic proximity Read

Liver Pyruvate Kinase Promotes NAFLD/NASH in Both Mice and Humans in a Sex-Specific Manner.Semantic proximity Read

A Systems Biology and Generative Artificial Intelligence Framework for Rational Multi-Target Drug Design in Metabolic Dysfunction-Associated Steatotic Liver Disease: Proof-of-Concept Identification of HPM-001Semantic proximity Read

The Effect of Cardiometabolic Drugs on Non-Alcoholic Fatty Liver Disease (NAFLD), Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD), and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)Semantic proximity Read